Master of Science, The Ohio State University, 2016, Biomedical Sciences

Sorafenib therapy has been shown to have only a small clinical benefit for liver cancer patients. There is an urgent needed to develop new therapeutic strategies for the treatment of advanced stage HCC. In this report, we screened several repurposed therapeutics in order to identify synergistic drug combinations. We demonstrate that the combination of 2-deoxy-glucose and sorafenib drastically inhibit HCC cell viability in Hep3B, Huh7 and sorafenib resistant Huh7 cells. Cell cycle analysis revealed that this therapeutic combination induced complete G0/G1 arrested HCC cells. Our studies suggest that this cell-cycle arrest is due to the depletion of cellular ATP. Overall, this report provides strong evidence for the clinical potential of sorafenib + 2-deoxyglucose combination therapy.

Committee: Samson Jacob PhD (Advisor); Kalpana Ghoshal PhD (Committee Member) Subjects: Medicine; Molecular Biology; Therapy